-
公开(公告)号：US20160208004A1
公开(公告)日：2016-07-21
申请号：US14994108
申请日：2016-01-12
Applicant: AMGEN INC.
Inventor： Alison L. Budelsky , Michael R. Comeau , Joel E. Tocker
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/00 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/76
Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.
Abstract translation: 本发明涉及白细胞介素-17配体和受体家族成员以及IL-17受体A和IL-17受体C形成具有生物活性的异聚受体复合物的发现。 公开了IL-17RA-IL-17RB异聚受体复合物的拮抗剂，以及各种使用方法。
-
公开(公告)号：US20140322238A1
公开(公告)日：2014-10-30
申请号：US14263534
申请日：2014-04-28
Applicant: Amgen Inc.
Inventor： Alison L. Budelsky , Michael R. Comeau , Joel E. Tocker
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/00 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/76
Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.
Abstract translation: 本发明涉及白细胞介素-17配体和受体家族成员以及IL-17受体A和IL-17受体C形成具有生物活性的异聚受体复合物的发现。 公开了IL-17RA-IL-17RB异聚受体复合物的拮抗剂，以及各种使用方法。
-
公开(公告)号：US20160159914A1
公开(公告)日：2016-06-09
申请号：US14886565
申请日：2015-10-19
Applicant: AMGEN INC.
Inventor： Alison L. Budelsky , Jennifer E. Towne , Yu Zhang , Lori Siegel , Antony Symons
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor E form a heteromeric receptor complex that is biologically active, and that IL-17C activity requires the IL-17RA-IL-17RE heteromeric receptor complex. Antagonists of the IL-17RA-IL-17RE heteromeric receptor complex are disclosed, as well as various methods of use.
Abstract translation: 本发明涉及白细胞介素-17配体和受体家族成员以及IL-17受体A和IL-17受体E形成具有生物活性的异聚受体复合物的发现，并且IL-17C活性需要IL-17RA- IL-17RE异聚受体复合物。 公开了IL-17RA-IL-17RE异聚受体复合物的拮抗剂以及各种使用方法。
-
公开(公告)号：US20170114140A1
公开(公告)日：2017-04-27
申请号：US15341870
申请日：2016-11-02
Applicant: KIRIN-AMGEN, INC.
Inventor： Alison L. Budelsky , Michael R. Comeau , Joel E. Tocker
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/00 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/76
Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.
-
-
-
Search Results
4
records
(took 0.011 seconds)
